‘Remarkable Interest’: Madrigal Touts Early Launch Progress for First MASH Drug Rezdiffra Despite VA Hurdle

With $1.1 billion cash on Madrigal Pharmaceuticals’ balance sheet, CEO Bill Sibold believes the company can “fully resource” the launch of Rezdiffra, the first FDA-approved therapy for fatty liver disease.